Tarsus Pharmaceuticals Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Tarsus Pharmaceuticals Inc 's ROA in the second quarter of 2026?
Tarsus Pharmaceuticals Inc recorded a cumulative net loss of $-46 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -8.12%.

However, within the Healthcare sector 281 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3155, from total ROA ranking in the first quarter of 2026 at 3849.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	24.34 %	16.62 %	50 %	39.88 %	30.55 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-46	-48	-66	-81	-92
Return On Assets (TTM)	-8.12 %	-8.9 %	-12.74 %	-17.12 %	-21.07 %
TARS's Total Ranking	# 3155	# 3849	# 3478	# 3604	# 3761
Total Assets (TTM) in million	611	585	566	526	492
Seq. Total Assets Change	4.47 %	3.35 %	7.6 %	7.03 %	-2.02 %
Seq. Net Income Change	-	-	-	-	-

TARS's 5 Years Annual ROA >> Back to TARS Management Effectiveness >> Compare TARS ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 29
Sector	# 282
Overall	# 3099

Return On Assets Statistics
High	Average	Low
72.49 %	-17.61 %	-58.2 %
(Dec 31 2020)		(Dec 31 2023)

Financial Statements
Tarsus Pharmaceuticals Inc 's Assets	$ 611 million	TARS's Balance sheet
Tarsus Pharmaceuticals Inc 's Income	$ -19 million	Quarterly TARS's Income Statement
TARS's Income by Division		See TARS's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	50 %	41.81 %	16.59 %	27.71 %	3.92 %
Total Assets in million	566	377	266	228	179
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-66	-116	-136	-62	-14
Annual Return On Assets	-11.73 %	-30.62 %	-51.07 %	-27.2 %	-7.74 %

TARS's 5 Years Annual ROA >> Back to TARS Management Effectiveness >> Compare TARS ROA to its Competitors

More Return On Assets Ratios
TARS's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
TARS's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for TARS's Competitors
Subscribers only: Roa for Tarsus Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for TARS's Customers

You may also want to know
TARS's Roi	TARS's Inventory Turnover Ratio	TARS's Growth Rates	TARS's Dividend Comparisons
	TARS's Profitability Ratios	TARS's Asset Turnover Ratio	TARS's Dividend Growth
TARS's Roe	TARS's Valuation Ratios	TARS's Financial Strength Ratios	TARS's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:39:03+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.